Furthermore, the combination therapy also reduced viral-induced PD-L1+ DCs, MDSCs, TAM, and Treg cell population, severely depleting the co-suppressed molecular-double-positive PD-1+CD8+ T cell population, resulting in reduced tumor load and improved survival [15]. The gene discussed is CD8A; the disease is neoplasm.